Big Boost to India's Covid-19 fight: India's first nasal vaccine cleared for use
BBV154 has been specifically formulated to allow intranasal delivery. In addition, the nasal delivery system has been designed and developed to be cost-effective in low and middle-income countries, the vaccine maker had said.
The Hyderabad-based firm completed clinical trials of the nasal vaccine with about 4,000 volunteers and there is no side effect or adverse reaction reported so far, company sources had said. Pic: Reuters/ Representational image